Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPM1D | O15297 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401954 | 0.83 | KMT2A (0.39) | CPB2KMT2AMETAP2CCR1METAP1 | |
| SCHEMBL742779 | 0.80 | CTSS (0.50) | KMT2AEPHX1RENCTSSCTSK | |
| SCHEMBL3725538 | 0.80 | CTSS (0.50) | KMT2AEPHX1RENCTSSCTSK | |
| SCHEMBL13737104 | 0.80 | CPB2 (0.55) | CPB2KMT2APPM1DCCR1EPHX1 | |
| SCHEMBL14975157 | 0.80 | L3MBTL1 (0.43) | KMT2AEPHX1HPGD | |
| SCHEMBL3330425 | 0.80 | METAP2 (0.36) | METAP2CCR1METAP1EPHX1REN | |
| SCHEMBL6477536 | 0.79 | ALDH1A1 (0.43) | CPB2KMT2AMETAP2METAP1REN | |
| SCHEMBL6477529 | 0.79 | ALDH1A1 (0.43) | CPB2KMT2AMETAP2METAP1REN | |
| SCHEMBL2008481 | 0.77 | ALDH1A1 (0.51) | KMT2AEPHX1RENCTSSCTSK | |
| SCHEMBL3729020 | 0.77 | SMN1; SMN2 (0.38) | KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161254-A1 | HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | CPB2 758/4885KMT2A 4134/4885PPM1D 1345/4885 |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | CTSB, CSTB, CTSF | CPB2 44/4885KMT2A 4689/4885PPM1D 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.